NEW YORK – Immuneering on Thursday said it signed a clinical supply agreement with Regeneron to obtain the anti-PD-1 therapy Libtayo (cemiplimab) for a Phase IIa trial testing Immuneering's MEK ...

Shares of Regeneron Pharmaceuticals have plunged more than 30% over the past six months, but one Wall Street analyst believes ...

Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with ...

CAMBRIDGE, Mass. - Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company with a market capitalization of $59.31 million, has entered into a clinical supply agreement with Regeneron ...

马萨诸塞州剑桥市 - 市值5,931万美元的临床阶段肿瘤公司Immuneering Corporation (NASDAQ: IMRX )与Regeneron制药公司达成临床供应协议，评估其主要产品候选药物IMM-1-104与Regeneron的抗PD-1疗法Libtayo（cemiplimab）的联合用药潜力。根据 InvestingPro ...

Detailed price information for Immuneering Corp Cl A (IMRX-Q) from The Globe and Mail including charting and trades.

Busà Photography / Getty Images Many people believe that being wealthy means having a nice house, a late-model car, and a summer cottage, but the kind of money possessed by the wealthiest 1% of ...

The pharma world , esp the big boys dont play clean .. IMM have now done their job and its now down to a big boys to finish it or delay it .. The conference would have been the place to close the deal ...

IMM-1-104 combined with mGnP shows promising efficacy and tolerability in first-line pancreatic cancer, with a 43% ORR and 86% DCR among seven patients. IMM-1-104 demonstrated target lesion shrinkage ...

(1) when that person’s mother was unlawfully present in the United States and the person’s father was not a United States citizen or lawful permanent resident at the time of said person’s ...

生物制药公司Immuneering Corp (NASDAQ:IMRX)市值为6334万美元，该公司宣布其正在进行的IMM-1-104治疗晚期RAS突变实体瘤的2a期临床试验中期数据令人鼓舞。 根据InvestingPro分析，该公司保持强劲的流动性，流动比率为7.99，尽管面临显著的现金消耗挑战。今天，公司披露该 ...

Copyright 2025 The Associated Press. All Rights Reserved. Toronto Raptors forward Scottie Barnes (4) and Golden State Warriors forward Gui Santos (15) vie for control ...